Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, +380

The Lancet

Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease +5

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, +632

Journal of Hepatology

FibrosisHepatologyLiver PhysiologyClinical TrialsPathology +7

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Stephen A. Harrison, Peter Ruane, B. Freilich, +10

Nature Medicine

HepatologyLiver PhysiologyPharmacologyNon-alcoholic SteatohepatitisLiver Disease +2

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial

Keyur Patel, Stephen A. Harrison, Magdy Elkhashab, +21

Hepatology

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

David Jones, Pol Boudes, Mark G. Swain, +33

˜The œLancet. Gastroenterology & hepatology

Molecular PharmacologySelective Ppar-δ AgonistHepatologyBiliary TractMedicine +9

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients

Paul J. Pockros, Michael Fuchs, B. Freilich, +9

Liver International

Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Guadalupe García–Tsao, Jaime Bosch, Zeid Kayali, +71

Journal of Hepatology

Severe Portal HypertensionHepatologyLiver PhysiologyGastroenterologyPlacebo-controlled Trial +6

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green, +93

Gastroenterology

Difference Between LatiglutenaseVillous AtrophyClinical PresentationCeliac DiseaseMedicine +1

Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis

Andrew J. Muir, Fred Poordad, Jacob Lalezari, +22

JAMA

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma

Imane El Dika, Ho Yeong Lim, Wei Peng Yong, +11

The Oncologist